Wockhardt gets FDA's blessing for generic Zytiga
Wockhardt recently received the Food and Drug Administration's green light for its generic Zytiga (abiraterone acetate). The generic of Johnson & Johnson's metastatic prostate cancer treatment will be available in a 250 mg dosage strength.
The product had a market value of $1.6 billion, according to December 2018 IQVIA data.
“This is one more product in Wockhardt’s growing portfolio of oncology products in the U.S. and has several pending ANDA’s for oncology products” Wockhardt founder chaimran and group CEO Habil Khorakiwala, said. “Along with oncology products, specialty products remain a focus area for our U.S. business and for creating a sustainable growth worldwide.”
The product is being manufactured at a contract manufacturing facility, based near Hyderabad, India.
The product had a market value of $1.6 billion, according to December 2018 IQVIA data.
“This is one more product in Wockhardt’s growing portfolio of oncology products in the U.S. and has several pending ANDA’s for oncology products” Wockhardt founder chaimran and group CEO Habil Khorakiwala, said. “Along with oncology products, specialty products remain a focus area for our U.S. business and for creating a sustainable growth worldwide.”
The product is being manufactured at a contract manufacturing facility, based near Hyderabad, India.